

Organovo To Present At 2012 Bio Investor Forum

October 2, 2012 12:00 PM ET

SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- **Organovo Holdings, Inc.** (OTCQB: ONVO) ("Organovo"), a developer and manufacturer of functional human tissues using a novel three-dimensional bioprinting technology, today announced that Keith Murphy, Chairman and Chief Executive Officer, will present at the upcoming 11th Annual BIO Investor Forum in San Francisco, CA. Mr. Murphy is expected to present on Tuesday, October 9, 2012 at 3:00 p.m. PDT. The conference will be held at The Palace Hotel in San Francisco on October 9-10.

About Organovo Holdings, Inc.

Organovo designs and creates functional human tissues using a proprietary three dimensional bioprinting technology. The Company focuses on developing a range of human tissues and disease models for medical research and therapeutic applications. The Company's NovoGen three-dimensional bioprinting technology uses a specialized automated platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's technology can also be applied to create surgical tissues for direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit <http://www.organovo.com>.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current report on Form 8-K/A filed on May 11, 2012. We do not undertake to update these forward-looking statements made by us.

SOURCE Organovo Holdings, Inc.

Investor Contact: Barry Michaels, Chief Financial Officer, 1-858-224-1003; Gerry Amato, Booke and Company, Investor Relations, admin@bookeandco.com; Media Contact: Mike Renard, Exec. VP, Commercial Operations, 1-858-224-1006, mrenard@organovo.com